Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Recent Press Releases
More >>
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Investor Downloads

Download Documentation Ponatinib Efficacy and Safety in Patients with the T315I Mutation – ASH 2014
Download Documentation Ponatinib Phase 2 PACE Update – ASH 2014
Download Documentation Ponatinib Phase 1 Update – ASH 2014
Download Documentation Corporate Presentation
More >>

ARIAD Stock Price: $7.22

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 12/19/14

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.61 (9.23%)
DAY LOW$6.59
52 WK. HIGH$9.83
Minimum 20 minute delay
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

You are now leaving this website. If you would like to continue, click Continue.